Per- and polyfluoroalkyl substances: evaluation of liver effects using in vivo data - PFAS/2023/06

Table 2 Lowest POD for PFAS based on liver effects - PFSAs

PFAS/2023/06

Last updated: 25 September 2025

This is a paper for discussion. This does not represent the views of the Committee and should not be cited.

*Derived by contractor; NA – not applicable. 

Substance / reference / table 

Sex, strain and species 

(Duration) 

NOAEL/LOAEL mg/kg bw/day 

Effect at LOAEL 

PFBS 

Chen et al. (2022)  

Table 17 

Male C57BL/6 mice,  

28 days. 

 

Males: 2 / 104. 

 

 

↑ apoptosis  

↓ CAT activity  

Changes in hepatic lipidome.  

PFHxS 

Butenhoff et al. (2009) 

Table 18 

Chang et al. (2018) 

Table 18 

Male Crl:CD®(SD) 

IGS BR VAF/Plus® 

42 days. 

Male Crl:CD1 mice 

42 days. 

Males: NA / 0.3. 

 

 

 

 

 

↓ serum cholesterol,  

↑ centrilobular hypertrophy. 

 

 

PFOS 

Butenhoff et al. (2012b) 

Table 19 

Male and female Crl:CD®(SD) 

IGS BR rats,  

104 weeks.  

Males/females: 0.024 / 0.098. 

Male  

↑ hepatocellular centrilobular hypertrophy  

↑ cystic hepatocellular  

Degeneration. 

Female 

↑ hepatocellular periportal vacuolation 

↓ serum total cholesterol.